In the present study, an attempt was made to prepare oral nanosuspensions of Irbesartan which is an angiotensin II receptor antagonist used mainly for the treatment of hypertension, in order to overcome bioavailability problems, to reduce dose dependent side effects and frequency of administration. Nanosuspension containing the drug was prepared by precipitation method using combinations of polymers (such as PVP-k15, Tween 80, methanol, SLS, and Polaxomer F127). Estimation of Irbesartan was carried out spectrophotometrically at 260 nm. The Oral nanosuspension were evaluated for various physical and biological parameters, drug content uniformity, entrapment efficiency, scanning electron microscopy, in-vitro drug release, short-term stability, and drug-excipient interactions (FTIR) indicates that all were within limits. In-vitro drug release studies of all the formulations were studied of that formulation F9 shows 100.02 % of drug release within 20 min. and follows first order release kinetics. Short-term stability studies (40±2° C/75±5% RH for 3 months) indicated that the oral nanosuspension are stable with respect to drug content and dissolution. IR spectroscopic studies indicated that there are no drugexcipient interactions.
